Drug Shortage Report for SUBLOCADE
Report ID | 155534 |
Drug Identification Number | 02483092 |
Brand name | SUBLOCADE |
Common or Proper name | SUBLOCADE® (buprenorphine extended-release injection) 300 mg / 1.5 mL |
Company Name | INDIVIOR UK LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | BUPRENORPHINE |
Strength(s) | 300MG |
Dosage form(s) | SOLUTION (EXTENDED RELEASE) |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 1 syringe/pack |
ATC code | N07BC |
ATC description | |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2022-03-01 |
Actual start date | 2022-03-01 |
Estimated end date | 2022-03-05 |
Actual end date | 2022-03-02 |
Shortage status | Resolved |
Updated date | 2022-03-03 |
Company comments | There is an anticipated short-term backorder of SUBLOCADE® 300 mg supply, that may impact some pharmacies in Canada, for a few days during the first week of March. The anticipated shortage is caused by transportation challenges in North America and will impact the 300 mg dosage strength only. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | THE CHAPLEO BUILDING, HENRY BOOT WAY HULL, -- UNITED KINGDOM HU4 7DY |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2022-03-03 | English | Compare |
v7 | 2022-03-02 | French | Compare |
v6 | 2022-03-02 | English | Compare |
v5 | 2022-03-02 | English | Compare |
v4 | 2022-03-01 | French | Compare |
v3 | 2022-03-01 | English | Compare |
v2 | 2022-02-24 | French | Compare |
v1 | 2022-02-24 | English | Compare |
Showing 1 to 8 of 8